{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:04:27Z","timestamp":1789131867791,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-026-00621-3","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:55:14Z","timestamp":1770134114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world effectiveness and safety of upadacitinib in Japanese patients with rheumatoid arthritis: impact of age, renal function, and low-dose therapy"],"prefix":"10.1186","volume":"10","author":[{"given":"Yuto","family":"Tanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-8678","authenticated-orcid":false,"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"10055","key":"621_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"key":"621_CR2","doi-asserted-by":"publisher","first-page":"10922","DOI":"10.3390\/ijms222010922","volume":"22","author":"N Kondo","year":"2021","unstructured":"Kondo N, Kobayashi D, Kuroda T. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021;22:10922.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"621_CR3","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/cells10112857","volume":"10","author":"AF Radu","year":"2021","unstructured":"Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11):2857.","journal-title":"Cells"},{"issue":"6","key":"621_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/mr\/roae049","volume":"34","author":"Y Nakayama","year":"2024","unstructured":"Nakayama Y, Nagata W, Takeuchi Y, Fukui S, Fujita Y, Hosokawa Y, et al. Systematic review and meta-analysis for the 2024 update of the Japan college of rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2024;34(6):1079\u201394.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"621_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli M, Kerschbaumer A, Kastrati K, Ghoreschi K, Gadina M, Heinz LX, et al. Selectivity, efficacy, and safety of jakinibs: new evidence for a still evolving story. Ann Rheum Dis. 2024;83(2):139\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"621_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/biom10071002","volume":"10","author":"J Angelini","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L, et al. JAK inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. 2020;10(7):1002.","journal-title":"Biomolecules"},{"issue":"4","key":"621_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo S, Nakayamada S, Tanaka Y. JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs. 2023;32(4):333\u201344.","journal-title":"Expert Opin Investig Drugs"},{"issue":"10139","key":"621_CR8","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of Upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (SELECT-NEXT): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503\u201312.","journal-title":"Lancet"},{"issue":"11","key":"621_CR9","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788\u2013800.","journal-title":"Arthritis Rheumatol"},{"issue":"10139","key":"621_CR10","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of Upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND): a double-blind, randomized controlled phase 3 trial. Lancet. 2018;391(10139):2513\u201324.","journal-title":"Lancet"},{"issue":"16","key":"621_CR11","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of Upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383(16):1511\u201321.","journal-title":"N Engl J Med"},{"issue":"10188","key":"621_CR12","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomized, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303\u201311.","journal-title":"Lancet"},{"issue":"10","key":"621_CR13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed MF, Chen S, et al. Efficacy and safety of Upadacitinib monotherapy in methotrexate-na\u00efve patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multicountry, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72(10):1607\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"621_CR14","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","volume":"59","author":"H Kameda","year":"2020","unstructured":"Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, et al. Efficacy and safety of Upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study. Rheumatology (Oxford). 2020;59:3303\u201313.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"621_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","volume":"23","author":"H Kameda","year":"2021","unstructured":"Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Yokoyama M, et al. Efficacy and safety of Upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther. 2021;23(1):9.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"621_CR16","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1093\/rheumatology\/kead543","volume":"63","author":"S Hayashi","year":"2024","unstructured":"Hayashi S, Tachibana S, Maeda T, Yamashita M, Shirasugi I, Yamamoto Y, et al. Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Rheumatology (Oxford). 2024;63(11):3033\u201341. https:\/\/doi.org\/10.1093\/rheumatology\/kead543. PMID:37924201.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"621_CR17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/art.11465","volume":"49","author":"Y Matsuda","year":"2003","unstructured":"Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, Saito T, et al. Validation of a Japanese version of the Stanford health assessment questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49(6):784\u20138.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"621_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/ggi.13118","volume":"17","author":"Y Ouchi","year":"2017","unstructured":"Ouchi Y, Rakugi H, Arai H, Akishita M, Ito H, Toba K, Kai I, Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Redefining the elderly as aged 75 years and older: proposal from the joint committee of Japan gerontological society and the Japan geriatrics society. Geriatr Gerontol Int. 2017;17(7):1045\u20137. https:\/\/doi.org\/10.1111\/ggi.13118.","journal-title":"Geriatr Gerontol Int"},{"issue":"3","key":"621_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"621_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","volume":"140","author":"O Steinbrocker","year":"1949","unstructured":"Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659\u201362.","journal-title":"J Am Med Assoc"},{"issue":"11","key":"621_CR21","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1093\/rheumatology\/keae435","volume":"63","author":"JS Smolen","year":"2024","unstructured":"Smolen JS, Taylor PC, Tanaka Y, Takeuchi T, Hashimoto M, Cara C, et al. Impact of high rheumatoid factor levels on treatment outcomes with certolizumab Pegol and adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2024;63(11):3015\u201324.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"621_CR22","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/mr\/roaf029","volume":"35","author":"Y Etani","year":"2025","unstructured":"Etani Y, Okita Y, Maeda Y, Tsujimoto K, Hirao M, Onishi A, et al. Distinct impact of RF and ACPA titer on the effectiveness and persistency of biologics and JAK inhibitors: the ANSWER cohort study. Mod Rheumatol. 2025;35(5):820\u20139.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"621_CR23","first-page":"390","volume":"35","author":"JR Curtis","year":"2017","unstructured":"Curtis JR, Schulze-Koops H, Takiya L, Mebus CA, Terry KK, Biswas P, et al. Efficacy and safety of Tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(3):390\u2013400.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"621_CR24","doi-asserted-by":"publisher","first-page":"e003648","DOI":"10.1136\/rmdopen-2023-003648","volume":"9","author":"H Bower","year":"2023","unstructured":"Bower H, Frisell T, di Giuseppe D, Delcoigne B, Lindstr\u00f6m U, Turesson C, et al. Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b\/tsDMARDs in Sweden. RMD Open. 2023;9(4):e003648. https:\/\/doi.org\/10.1136\/rmdopen-2023-003648.","journal-title":"RMD Open"},{"issue":"4","key":"621_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"key":"621_CR26","unstructured":"Japan College of Rheumatology. The warning of the occurrence of interstitial lung disease and Pneumocystis jirovecii during upadacitinib (Rinvoq) treatment and recommendation of proper use. JCR Letter. 2023; Nov 30. Available from: https:\/\/www.ryumachi-jp.com\/jcr_wp\/media\/2024\/04\/news20240401.pdf."},{"issue":"2","key":"621_CR27","doi-asserted-by":"publisher","first-page":"e005051","DOI":"10.1136\/rmdopen-2024-005051","volume":"11","author":"JS Smolen","year":"2025","unstructured":"Smolen JS, Emery P, Rigby W, Tanaka Y, Vargas JI, Jain M, et al. Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomized study. RMD Open. 2025;11(2):e005051.","journal-title":"RMD Open"},{"issue":"3","key":"621_CR28","doi-asserted-by":"publisher","first-page":"350","DOI":"10.46497\/ArchRheumatol.2024.10645","volume":"39","author":"M Tada","year":"2024","unstructured":"Tada M, Okano T, Mamoto K, Yamada Y, Orita K, Mandai K, et al. Comparison of creatine kinase elevation caused by Janus kinase inhibitors and Interleukin 6 inhibitors in patients with rheumatoid arthritis: a propensity score\u2013matched study. Arch Rheumatol. 2024;39(3):350\u20137.","journal-title":"Arch Rheumatol"},{"issue":"1","key":"621_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13075-015-0612-7","volume":"17","author":"JM Kremer","year":"2015","unstructured":"Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony HP, Lee SK, et al. Evaluation of the effect of Tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Res Ther. 2015;17(1):95.","journal-title":"Arthritis Res Ther"},{"issue":"23","key":"621_CR30","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.3390\/jcm11236894","volume":"11","author":"A Makris","year":"2022","unstructured":"Makris A, Barkas F, Sfikakis PP, Liberopoulos E, Agouridis AP. The effect of Upadacitinib on lipid profile and cardiovascular events: a meta-analysis of randomized controlled trials. J Clin Med. 2022;11(23):6894.","journal-title":"J Clin Med"},{"issue":"3","key":"621_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","volume":"41","author":"N Li","year":"2022","unstructured":"Li N, Gou ZP, Du SQ, Zhu XH, Lin H, Liang XF, et al. Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis. Clin Rheumatol. 2022;41(3):677\u201388.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"621_CR32","first-page":"64","volume":"35","author":"S Ito","year":"2023","unstructured":"Ito S, Sudo M, Takamura S, Kobayashi D, Funamura K, Abe A, et al. Safety and influence of the Recombinant Zoster vaccine on disease activity in Japanese patients with rheumatic diseases. Clin Rheumatol Relat Res. 2023;35(2):64\u201376.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"621_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, et al. 2022 American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023;75(3):449\u201364.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00621-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00621-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00621-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:04:32Z","timestamp":1772582672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-026-00621-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00621-3","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the Japanese Ministry of Health, Labour and Welfare. Study protocol was reviewed and approved by the Ethics Committee of Niigata University (approval number: 2022-0012). The requirement for informed consent was waived due to the retrospective nature of the study and the use of de-identified clinical data. Institutional permissions were obtained from all participating centers prior to data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yuto Tanno (YT) has received lecture fees from AbbVie GK and Asahi Kasei Pharma Corp. Naoki Kondo (NK) has received lecture fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Taisho Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. Satoshi Ito (SI) has received lecture fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., AYUMI Pharmaceutical Corporation, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Sandoz K.K., Taisho Toyama Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. Yoko Wada (YW) has received lecture fees from AbbVie GK, Asahi Kasei Pharma Corp., Eisai Co., Ltd., Eli Lilly Japan K.K., and Taisho Pharmaceutical Co., Ltd. Takeshi Kuroda (TK) has received lecture fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Ltd., Sandoz K.K., and Taisho Pharmaceutical Co., Ltd. Daisuke Kobayashi (DK) has received lecture fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Ltd., Sanofi K.K., Sandoz K.K., Taisho Toyama Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}